Navigation Links
Lotus Pharmaceuticals to Exhibit at the 63rd PHARMCHINA
Date:4/22/2010

BEIJING, April 22 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company"), a growing developer, manufacturer and seller of medicine and drugs in the People's Republic of China (the "PRC"), today reported it will exhibit at the 63rd PHARMCHINA.

    Time:          April 24-26, 2010
    Venue:         International Convention Center, Xiamen
    Primary Booth: Liang Fang, Beijing Delegate Area

The Company has attended PHARMCHINA exhibitions every year since 1996 as a way to strengthen customer relationships and attract new distributors, while promoting its products.

Lotus will continue to market both its self-branded and self-produced drugs that have established market shares in China. Lotus will also introduce its upcoming innovative asthma drug Laevo-Bambutero, together with two other pipeline drugs Gliclazide-Controlled Release Tablets for type 2 diabetes and Isosorbide Mononitrate-Sustained Release Tablets for coronary artery disease.

About PHARMCHINA

PHARMCHINA has been the largest and most recognized exhibition in the Chinese pharmaceutical industry over the last thirty years. With a gross floor area of more than 60,000 square meters and leading professional and academic forums, it attracts more than 1,900 exhibitors. PHARMCHINA is a diversified trading and exchange platform for pharmaceutical companies. For more information, please see http://www.pharmchina.com.cn .

About Lotus Pharmaceuticals, Inc. ( http://www.lotuspharma.com )

Lotus Pharmaceuticals, Inc. is a growing developer and producer of drugs and a licensed national seller of pharmaceutical items in the PRC. Lotus operates its business through its two controlled entities: Liang Fang Pharmaceutical, Ltd. and En Ze Jia Shi Pharmaceutical, Ltd. Lotus' current drug development is focused on the treatment of cerebro-cardiovascular disease, asthma and diabetes. Liang Fang sells drugs directly and indirectly through its national sales channels to hospitals, clinics and drugs stores in 30 provinces of the PRC.

    Lotus Pharmaceuticals, Inc.
     Yan ZENG, CFO
     Tel:   +86-10-6389-9868
     Email: zy@lotuspharma.com


'/>"/>
SOURCE Lotus Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lotus Pharmaceuticals Reports Groundbreaking Ceremony
2. Lotus Pharmaceuticals, Inc. Strengthens Beijing Presence with Direct Sales to Drug Stores
3. Lotus Pharmaceuticals, Inc. to Exhibit at the 62nd PHARMCHINA
4. Lotus Pharmaceuticals, Inc. Reports Third-Quarter 2009 Results
5. Lotus Pharmaceuticals, Inc.s New Drug Laevo-Bambutero Begins Evaluation for Clinical Trials
6. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
7. pHase Pharmaceuticals Announces New Venture
8. Ampio Pharmaceuticals to Acquire DMI Biosciences, Inc.
9. Sagent Pharmaceuticals Announces U.S. FDA Tentative Approval of Additional Adenosine Injection, USP Vial Presentations
10. Biostar Pharmaceuticals Approved for Listing on NASDAQ Global Market
11. Renhuang Pharmaceuticals Announces Continual Improvement in Days Sales Outstanding
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... Feb. 4, 2016  SciClone Pharmaceuticals, Inc. (NASDAQ: ... has entered into a settlement agreement with the ... resolving the SEC,s investigation into possible violations of ... terms of the settlement agreement, SciClone has agreed ... disgorgement, pre-judgment interest and a penalty.  This payment ...
(Date:2/4/2016)... -- Global Immunology Market to 2022 - Large ... growth Summary Immune-mediated inflammatory diseases are ... affect 5–7% of western populations. Although they are ... key patient demographics, they are pathophysiologically linked, being ... inappropriate immune response. Generally, disease-modifying anti-rheumatic drugs, a ...
(Date:2/4/2016)...  Aethlon Medical, Inc. (Nasdaq: AEMD ), ... treat life-threatening diseases, today announced results for the ... 2015. --> --> ... our last quarterly call, we strategically advanced pre-clinical ... to establish the Aethlon Hemopurifier® as a leading ...
Breaking Medicine Technology:
(Date:2/5/2016)... York, New York (PRWEB) , ... February 05, 2016 , ... ... life? The answer may be at the tips of your toes. Foot massage, whether ... as well as pure comfort and relaxation. The American Board of Multiple Specialties ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... franchises from across the country gathered at the La Valencia Hotel in San ... PROSHRED Chicago was named the year’s most outstanding franchise, walking away with ...
(Date:2/5/2016)... ... 05, 2016 , ... Pivot Point Consulting, a leading national ... & Services for HIT Implementation Support & Staffing report with an outstanding score ... by healthcare executives, managers and clinicians representing over 4,500 hospitals and 2,500 clinics. ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... Colorize ... from on one drop zone to the next using Colorize's dynamic moving camera. Colorize ... project. This package includes a 3D slideshow environment with 1 to 5 focus points ...
(Date:2/5/2016)... ... 05, 2016 , ... Calls Blacklist has just been updated by mobile app ... the developer has fixed known bugs within the app. Calls Blacklist allows its users ... not consuming any of their device’s battery power or memory. It provides a powerful ...
Breaking Medicine News(10 mins):